Adaptive Clinical Trials: US FDA Offers More Advice On Bayesian Designs
Final guidance provides more details on clinical trial designs that use Bayesian adaptive features; says monitoring committee recommendations may deviate from the anticipated algorithm.
You may also be interested in...
BIO and PhRMA ask agency to provide more guidance on trial implementation, data integrity and novel data sources.
Draft guidance specifies documentation that must be submitted to FDA prior to conducting an adaptive trial, and what to include in an application.
Attorneys say the biggest step FDA could take to expand access to abortion medication would be to eliminate REMS requirement for mifepristone. Timeline notes steps Biden administration and Congress have taken since the Supreme Court’s ruling overturning the right to an abortion.